- Proteins and Peptides
- Lysates and Cell Lines
The CiteAb Lifetime Achievement Award recognizes and promotes an individual who has made an outstanding contribution to the research antibody industry over a sustained period of time.
We're delighted to announce that Karen Padgett, founder of Novus Biologicals, has been recognized for her lifetime achievement in the research antibody industry. Karen is currently the VP of the Antibody Business Unit (representing both Novus and R&D Systems) and Digital Marketing at Bio-Techne. Karen has earned her place as a global leader in the research antibody industry, through her unfailing commitment, drive and positivity over the last two decades, and without ever compromising the integrity that defines her company as an industry leader.
Over 20 years of research antibody leadership at Novus Biologicals
Karen founded Novus Biologicals in 1996, through her own skill, focus, hard work and initiative; a company that rapidly became known for both the personalized service it provided and the rare ability to provide previously difficult to find, or develop novel antibodies, necessary to advance life science discovery. The name, "Novus," was chosen because it means novel, unusual, extraordinary in Latin which was the early product focus.
Karen's first antibodies were built through collaborations with leading academic scientists, who helped supply and test many of the difficult antibody targets scientists in the field were clamoring to find. This was possible due to the warm and trusting relationships she developed in the field. These relationships continue today and have expanded significantly.
Karen's industry leadership and influence has also been exhibited through enthusiastic support of various antibody industry and publisher initiatives to improve validation standards, including the F1000Research Antibody Validation Channel, the 2nd International Antibody Validation Meeting, Affinity Binder Knockdown Initiative, and The Science Exchange Cancer Biology Reproducibility Project. Her can-do personality has not diminished, and she is currently a stakeholder and moderator in the recent Global Biological Standard Institute meetings, for defining and raising antibody validation standards in the industry.
Comment from CiteAb
Dr Andrew Chalmers, Founder of CiteAb, said: "Judges for this award looked for a contribution that went beyond commercial success. Karen founded Novus Biologicals and developed the company…she continues to drive growth in the newly formed Bio-Techne."
"However, in addition to the growth of a powerful brand, Karen's contribution reaches further. Throughout her career, she has had a very clear focus on building collaborations with industry and academics and has been central to many initiatives that have resulted in the improvement of validation standards. She has also invested in the next generation of researchers through a long-standing worldwide student scholarship programme.
"Karen is widely respected and well-liked by her industry peers, not an easy feat for any individual while also generating positive commercial growth year-on-year. She is a very deserving winner of this prestigious award and along with my colleagues at CiteAb I wish her many congratulations."